Acusphere reaches deal with FDA
Article Thumbnail ImageJune 8, 2011 -- Ultrasound contrast developer Acusphere has signed a special protocol assessment agreement with the U.S. Food and Drug Administration (FDA) for the design of a new phase III study of its Imagify agent.
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking

The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease, according to Acusphere. The FDA had requested a placebo-controlled phase III trial for Imagify to supplement earlier trials that compared Imagify's efficacy with nuclear stress testing.

Based upon an enrollment of 900 patients, the company expects the new trial will cost approximately $15 million and require approximately two years to complete.